Bioxytran Inc banner

Bioxytran Inc
OTC:BIXT

Watchlist Manager
Bioxytran Inc Logo
Bioxytran Inc
OTC:BIXT
Watchlist
Price: 0.0407 USD -2.86% Market Closed
Market Cap: $4m

Bioxytran Inc
Investor Relations

BioXyTran, Inc. engages in the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen in tissues. The company is headquartered in Needham, Massachusetts. The company went IPO on 2010-01-05. The Company’s lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application that includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiaries, provides lead pharmaceutical drug candidate, ProLectin-Rx. ProLectin-Rx is a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, which is a type of galectin.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. David Platt Ph.D.
Chairman, CEO & President
No Bio Available
Mr. Ola Soderquist C.M.A., C.P.A., CM&AA, CMA, CPA, M.B.A.
CFO, Treasurer & Secretary
No Bio Available
Mr. Michael Sheikh B.S.
Chief Communication Officer
No Bio Available

Contacts

Address
MASSACHUSETTS
Needham
C/O Bioxytran, Inc., 75 2Nd Ave, Suite 605 Ste 605
Contacts
+16174941199.0
www.bioxytraninc.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett